Inventiva Announces Last Patient Visit in NATiV3 Phase 3 Clinical Trial of Lanifibranor in MASH

Phase 3LanifibranorNeutral

AI Analysis

Summary

Inventiva announced that the last patient visit has occurred in the NATiV3 Phase 3 clinical trial evaluating Lanifibranor for metabolic dysfunction-associated steatohepatitis (MASH).

Clinical Trial Data

Phase

Phase 3

Importance:5/10

Sentiment:

0.00

Phase 3Clinical TrialLanifibranorMASHNATiV3

Related Companies

$IVA

Read the original article

Published by yahoo_finance on September 2, 2026 8:05 PM

Read Original